Frontage Holdings Corporation (HKG:1521)
Hong Kong · Delayed Price · Currency is HKD 1.050
+0.010 (0.96%)
Apr 17, 2026, 11:57 AM HKT
Frontage Holdings Market Cap
Frontage Holdings has a market cap or net worth of 2.11 billion as of April 17, 2026. Its market cap has decreased by -1.69% in one year.
Market Cap
2.11B
Enterprise Value
2.81B
Revenue
2.00B
Ranking
n/a
PE Ratio
40.50
Stock Price
1.05
Market Cap Chart
Since May 30, 2019, Frontage Holdings's market cap has decreased from 6.73B to 2.11B, a decrease of -68.64%. That is a compound annual growth rate of -15.50%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 17, 2026 | 2.13B | 5.00% |
| Dec 31, 2025 | 2.03B | -43.71% |
| Dec 31, 2024 | 3.60B | -23.57% |
| Dec 29, 2023 | 4.71B | -20.20% |
| Dec 30, 2022 | 5.91B | -27.11% |
| Dec 31, 2021 | 8.10B | -6.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| May 30, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Jiangsu Recbio Technology | 3.15B |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 2.61B |
| SinoMab BioScience | 2.34B |
| Immunotech Biopharm | 2.27B |
| HighTide Therapeutics | 2.05B |
| Mabpharm | 1.88B |
| Cutia Therapeutics | 1.71B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.70B |